3. DATES COVERED (From - To) 01/19/2018-01/21/2018

4. TITLE AND SUBTITLE Plasmacytoma Infiltrating Leiomyoma in Multiple Myeloma

6. AUTHOR(S) Capt Eden, Rina

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 59th Clinical Research Division
1100 Willford Hall Loop, Bldg 4430
JBSA-Lackland, TX 78236-9908
210-292-7141

8. PERFORMING ORGANIZATION REPORT NUMBER 17538

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 59th Clinical Research Division
1100 Willford Hall Loop, Bldg 4430
JBSA-Lackland, TX 78236-9908
210-292-7141

10. SPONSOR/MONITOR'S ACRONYM(S) 

11. SPONSOR/MONITOR'S REPORT NUMBER(S) 

12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release. Distribution is unlimited.

13. SUPPLEMENTARY NOTES Texas Society of Pathologists Annual Meeting 2018, Houston, Texas, January 19-21, 2018

14. ABSTRACT Extraosseous plasmacytoma is rare within the female genital tract. Here, we report the case of a 55 year-old female with a history of multiple myeloma who presented with a six month history of postmenopausal vaginal bleeding. Speculum exam revealed a mass protruding through the cervical canal highly suggestive of a prolapsed leiomyoma. After surgical resection, gross examination of the presumptive myomectomy specimen revealed a 4cm white, whorled mass with no areas of necrosis or hemorrhage. Microscopically, the mass was comprised of a well-circumscribed proliferation of smooth muscle diffusely effaced and expanded by a population of CD138+, lambda light chain-restricted plasma cells. We hypothesize that a preexisting submucosal leiomyoma became colonized by neoplastic plasma cells with resultant expansion and protrusion of the leiomyoma through the cervical canal. This case highlights a rare presentation of an extraosseous plasmacytoma within the female genital tract and to our knowledge is the first reported case of a plasmacytoma involving a leiomyoma.

15. SUBJECT TERMS 

16. SECURITY CLASSIFICATION OF: 

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>b. ABSTRACT</th>
<th>c. THIS PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>UU</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

17. LIMITATION OF ABSTRACT UU

18. NUMBER OF PAGES 

19. NAME OF RESPONSIBLE PERSON Clarice Longoria

210-292-7141
Plasmacytoma Infiltrating Leiomyoma in Multiple Myeloma

Authors: Rina E. K. Eden, DO; Jean M. Covello, DO; Nathaniel E. Smith, MD

Department of Pathology and Area Laboratory Services, San Antonio Military Medical Center, Fort Sam Houston, TX, USA

Abstract

Extraosseous plasmacytoma is rare within the female genital tract. Here, we report the case of a 55 year-old female with a history of multiple myeloma who presented with a six month history of postmenopausal vaginal bleeding. Speculum exam revealed a mass protruding through the cervical canal highly suggestive of a prolapsed leiomyoma. After surgical resection, gross examination of the presumptive myomectomy specimen revealed a 4cm white, whorled mass with no areas of necrosis or hemorrhage. Microscopically, the mass was comprised of a well-circumscribed proliferation of smooth muscle diffusely effaced and expanded by a population of CD138+, lambda light chain-restricted plasma cells. We hypothesize that a preexisting submucosal leiomyoma became colonized by neoplastic plasma cells with resultant expansion and protrusion of the leiomyoma through the cervical canal. This case highlights a rare presentation of an extraosseous plasmacytoma within the female genital tract and to our knowledge is the first reported case of a plasmacytoma involving a leiomyoma.

Case Report

56 year-old postmenopausal female with recent history of relapsing multiple myeloma presented to the emergency department with worsening vaginal bleeding. On speculum exam, a smooth 4 cm mass with a 0.5cm stalk attached to the uterine cervix was observed. The physical exam was consistent with a prolapsing leiomyoma. The mass was removed under anesthesia and submitted to pathology for exam.

Gross Examination: White-tan, firm well-circumscribed mass measuring 4 x 2.5 x 2.5 cm with homogenous white-tan whorled cut surface with few punctate hemorrhages and negative for necrosis.

Histologic Examination: Tissue demonstrated atypical, diffuse population of plasma cells that were positive for CD138 and lambda light chain immunohistochemical stains. The background tissue showed a desmin positive fascicular smooth muscle population without atypia, consistent with a leiomyoma and clinical history of fibroid uterus.

Follow-up: Patient refused hysterectomy and was not reevaluated by gynecology-oncology. The patient’s multiple myeloma became refractory to chemotherapy and the patient was placed on hospice 7 months after the uterine plasmacytoma was removed.

Pathology

Figure A. Diffuse plasmacytic infiltrate expanding a smooth muscle mass, H & E stain (4x).

Figure B. CD 138 immunohistochemical stain demonstrating plasma cell distribution (4x).

Figure C. Lambda light chain immunohistochemical stain demonstrating the lambda restricted plasma cell population (4x).

Figure D. Desmin immunohistochemical stain demonstrating the residual leiomyoma (4x).

Discussion

Gynecologic presentation of solitary extramedullary plasmacytoma (SEMP) is rarely discussed in the literature. SEMP and multiple myeloma (MM) have drastically different management and prognoses. There have been only twenty-four cases of gynecologic plasmacytoma reported1, none of which have involved the myometrium or leiomyomata. Only three of the cases were determined to be related to systemic MM. Uterine cervix plasmacytomas treated with complete surgical resection with hysterectomy were found to have no gynecologic recurrence or progression at follow-up ranging from 3 months to 3.5 years later2-3. However, it is estimated that 30-50% of cases of SEMP will progress to systemic disease4. This may imply that a complete surgical resection of myometrial plasmacytoma would be beneficial in SEMP and may have benefit in MM involvement of the myometrium in addition to systemic treatment for symptomatic relief and prevention of gynecologic recurrence.

References


Acknowledgements:
Members of the diagnostic and clinical teams included Dr. Nicole P. Chappell, MD, staff obstetrician and gynecologist, Devin S. Cooper, MD, resident obstetrician and gynecologist, and Michael A. Wiggins, MD, staff hematologist and oncologist.

"The views expressed herein are those of the author(s) and do not reflect the official policy or position of the U.S. Army Medical Department, the U.S. Army Medical Command, the Department of the Army or the Department of Defense or the U.S. Government."